Bhavana Pothuri

Gynecologic Oncologist, parent, advocate for patients with Gyn cancer. Opinions are mine not NYU Langone School of Medicine

[Bhavana Pothuri @BPothuri]

What an honor to co-lead with @ketta LORUSSO and mentor @mdslightfoot on this practice changing trial. A nice win for pts with #EC with limited options. @GOG @SGO_org @myESMO @IGCSociety @Perlmutter_CC @gyncsm

[The GOG Foundation Inc. @GOG]

To read the full publication, click link in bio or go to https://t.co/eCbwNaohJQ.

@BPothuri #GOGPartners #GynecologicOncology #clinicaltrials #GOGF #clinicaltrials #endometrialcancer #ESMO26

[The GOG Foundation Inc. @GOG]

To read the full press release, click link in bio or go to https://t.co/pRT48K128o

#GynecologicOncology #GOGPartners #GOGF #clinicaltrials #endometrialcancer

[SGO @SGO_org]

On #NationalDayOfAction, SGO urges members to raise awareness about the proposed OMB rule and its potential impact on research.

Make your voice heard by taking this action alert.

https://t.co/ciBrtuZBL0

[NRG Oncology @NRGonc]

🔬Happy Birthday Marie Curie, a trailblazer whose groundbreaking discoveries transformed science & medicine, her legacy continues to inspire generations of researchers. We carry that spirit forward thru innovative research aimed at improving outcomes for patients. #WeWhoCurie Day

[Giuseppe Caruso, MD PhD @gcarusomd]

Rina-S is coming in the PROC setting, so what happens to MIRV? 🤔

Genmab has announced positive topline results from the phase 3 RAINFOL-02 trial in PROC: Rina-S vs investigator’s choice CHT improved both PFS (HR 0.29) and OS (HR 0.43).
👉 The most interesting part for me is the primary analysis set (PAS), where FRα-high patients had to be pretreated with MIRV: PFS HR 0.33 and OS HR 0.44.

Both drugs target FRα, but they are not the same:
🔹 MIRV: tubulin payload, works only in FRα-high tumors
🔹 Rina-S: TOP1i payload, active across FRα levels and apparently also after MIRV

💡 A hypothesis: the order matters?
✅ MIRV first → Rina-S next: MIRV clears the FRα-high cells, and Rina-S can still hit the FRα-low ones that are left.
❌ Rina-S first → MIRV next: very unlikely to work, as little FRα-high disease should be left.
And if GLORIOSA trial is positive, MIRV could move earlier, to maintenance in PSOC, with Rina-S kept for PROC.

Of course, this “ADC-opoly” board in ovarian cancer is getting crowded, with many more ADCs coming across all settings (1L, PSOC, PROC) and different targets…
Things are about to get very complex 🤯 but, on the bright side, there will be more and more options for our patients... even beyond ADCs.

@oncodaily - @OncoAlert - @DrKatyMoore - @GynMe4

[Oncology Tube @oncologytube]

VIDEO: ESMO 2026 — after platinum + PD-(L)1 in endometrial cancer, is a TROP2 ADC next? TroFuse-005: sac-TMT OS 19.0 vs 12.1 mo, HR 0.68 🧬🎯

👉 https://t.co/Pss3pj2ZVy

🔹 Phase 3, n=776: sacituzumab tirumotecan vs physician's choice (doxorubicin or paclitaxel)
🔹 BICR PFS 7.2 vs 3.9 mo (HR 0.59); ORR 35.1% vs 17.3%
🔹 Grade ≥3 AEs 69% vs 57%; treatment-related deaths <1% per arm

Investigational in the US: FDA priority review, PDUFA June 15, 2027. Presidential LBA11 + The Lancet (Oct 26, 2026).

@OncoAlert @BPothuri @GynCancerMD @rne_md @ShannonWestin @DrKatyMoore @PamSolimanMD @amandanfader @MirzaCPH @karenluMD @AngelesSecord @nicoleflemingmd @AmirJazaeri @RSalaniMD @FBackesMD @leitaomd @KatherineFuh @DrTewari @pedroramirezMD @ggardnermd @DebbieRic23 @David_Cohn_MD @StephanieLheur5 @JordynSilvs @DrBarbiOnc @drteplinsky @AinhoaMada @Ilaria_Colombo_ @mdslightfoot @JCohenMD @EmmaBarberMD @Britdavidsonmd @BarbaraAGoff @matei_dem @aaronshafer99

#ESMO26 #EndometrialCancer #GynOnc #ADC #OncologyTube #MedOnc

[NRG Oncology @NRGonc]

Application Deadline Approaching! NRG Oncology is currently accepting applications for travel awards to #NRG2027 in Las Vegas! Application window closes November 9th. More information can be found at https://t.co/HvRIdKyPN3

[Bhavana Pothuri @BPothuri]

This is a great program for new investigators- please apply! @SGO_org @GOG @nyulangone @Perlmutter_CC

[SGO @SGO_org]

FINAL CALL! Applications for the SGO/GOG-F BRIDGES Research Initiative close November 9.

Don't miss your chance to gain expert mentorship and clinical trial design experience.

Apply now!

#SGO #GynecologicOncology

[NSABP Foundation @NSABPFoundation]

#Clinicaltrialresearch is vital. "Every new medicine and treatment started with volunteers participating in clinical trials." Learn more: https://t.co/j7ox2HS0pF #NSABPFoundation #CancerResearch

[Mark Cuban @mcuban]

For those who say it’s time for universal care. I am all for it. It would be nice if we could find a way to reduce the cost of care and make it available to everyone, for anything.

But it will take work to get there. Other countries with Universal Care make “Most Things available to All People”. It’s not perfect.

In our country, we make “Everything available to Most People”.

The question for this country, unlike others, is how we can make the best possible care and therapies, regardless of cost, to everyone ?

Read @AbdulElSayed ‘s book on Medicare for All. He wisely had more questions than answers. Medicare for All ? Global Budgets ? Or something else ?

It’s a difficult path from where we are to “E4E” Healthcare. ?Everything for Everyone)

My hope is that we can put together a Simpson Bowles type, Blue Ribbon Commission. One that includes representatives of all stakeholders. From all different type of patients. Including rare disease parents. Rural and Urban Hospitals. The most expensive hospitals that offer unique care. Pharma companies that offer everything from genetics to Cell and Gene Therapies. You get the point

Some people think we can just tell all those working in the healthcare system what to do.

That’s the fastest way for this to fail. We need to be as close as we can to being on the same page. And we need to figure out a non partisan manner of running our American version of Universal Care.

No reason we can’t start now

[Dr. Anthony Letai @NCIDirector]

Cancer research runs on people who are just starting out. In 2026, @theNCI funded a record 147 new awards for early-stage investigators. I am looking forward to seeing what they discover and which future breakthroughs start in their labs.

[John P. Leonard, MD @JohnPLeonardMD]

@Aiims1742 kicking off the @Perlmutter_CC retreat - exciting things happening! @nyugrossman @nyulangone

[NYU Department of Medicine @NYULH_DeptofMed]

We are pleased to welcome Michelle Kang Kim, MD, PhD (@MichelleKimMD), a distinguished gastroenterologist and NIH-funded clinician-scientist, as the new Chair of the Department of Medicine @nyugrossman! Dr. Kim is renowned for her leadership, transformative research on gastrointestinal (GI) carcinoid and neuroendocrine tumors, and predictive models for the early detection of GI cancers. We are proud to welcome her to @NYULH_DeptofMed

Press Release: https://t.co/b2J709efkg

#Exceptionalism #Leadership #TranslationalResearch #ClinicalInnovation #MedTwitter #GITwitter

[The GOG Foundation Inc. @GOG]

GOG and ENGOT continue to advance global gynecologic cancer research, with 3 Phase 3 trials reaching important first-patient milestones. Thank you to all who make this work possible. #ENGOT #ClinicalTrials #OvarianCancer #GOGF #GOGP

[Dr. Anthony Letai @NCIDirector]

Alcohol can make quitting smoking harder and relapse more likely. @theNCI’s new Tobacco Control Monograph 24 looks at how tobacco and alcohol co-use affects cancer risk, and what that means for prevention and treatment. #LungCancerAwarenessMonth https://t.co/UiYzmNJmwH

[NYU Department of Medicine @NYULH_DeptofMed]

Congratulations to Maryann Kwa, MD, on her greatly deserved promotion to Associate Professor of Medicine. “I find it incredibly rewarding to support patients through their cancer journey, offering the latest systemic therapies tailored to each patient’s specific needs.” —Dr. Kwa

#Exceptionalism #FacultyAchievement #Oncology #CancerCare @Perlmutter_CC @JohnPLeonardMD @Aiims1742

[The GOG Foundation Inc. @GOG]

📣 More time to apply! The SGO/GOG-F BRIDGES Research Initiative deadline has been extended to November 9. Early-career investigators in gynecologic oncology can build clinical trial design skills, learn from expert mentors, and develop innovative research. Apply by Nov. 9!
#SGO

[BioMed Nexus @biomednexus]

@TargetedOnc @nyulangone @Perlmutter_CC @BPothuri The TroFuse-005 numbers: median OS 19.0 vs 12.1 months (HR 0.68), median PFS 7.2 vs 3.9 months (HR 0.59), response 35.1% vs 17.3%. The FDA set a June 15, 2027 action date with priority review.

[Bhavana Pothuri @BPothuri]

So honored as GOG PI to mentor @mdslightfoot on this practice changing trial. What an amazing win for pts w/ adv/rec #EC. The 1st ph3 ADC trial in #EC and 1st phase 3 TROP2 ADC trial in #gynca. Grateful to @LorussoDomenica &amp; @merck for colloboration. @myESMO @ASCO @SGO_org @GOG

[The ASCO Post @ASCOPost]

🚺 Phase III TroFuse-005 results show that sacituzumab tirumotecan significantly improved progression-free and overall survival vs standard chemotherapy in previously treated advanced or recurrent #EndometrialCancer.

▪️@mdslightfoot &amp; @BPothuri | #ESMO26

https://t.co/g6h2T1opaJ

[Bhavana Pothuri @BPothuri]

@ainhoa madariga and @Ilaria_Colombo_ was so great to discuss long term survival and potential “cure” in dMMR endometrial cancer- what a long way we have come with immune checkpoint inhibitors @myESMO @ASCO @SGO_org @GOG @nyulangone @Perlmutter_CC @gyncsm @ECANAwomen

[Ainhoa Madariaga @AinhoaMada]

Wrapping up an inspiring @myESMO

​💡 Honored to join the #YOC track to break down practical steps for leading academic &amp; investigator-initiated trials

​🔬 Loved diving into long-term ICI benefit in endometrial cancer alongside @BPothuri &amp; @Ilaria_Colombo_

​#GynCsm @H12Octubre